EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024

Jan 3, 2024

SEC Form 4/A — Form 4/A

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-12-28

Reporting Person: Lurker Nancy (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-28	Common Stock	G	52208.00	$0.00	Disposed	118351.00	Direct
2023-12-28	Common Stock	G	52208.00	$0.00	Acquired	52208.00	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-28	Stock Option (Right to Buy)	$13.13	G	31164.00	Disposed	2031-02-09	Common Stock (31164.00)	Direct
2023-12-28	Stock Option (Right to Buy)	$13.13	G	31164.00	Acquired	2031-02-09	Common Stock (31164.00)	Indirect
2023-12-28	Stock Option (Right to Buy)	$12.90	G	10906.00	Disposed	2030-02-28	Common Stock (10906.00)	Direct
2023-12-28	Stock Option (Right to Buy)	$12.90	G	10906.00	Acquired	2030-02-28	Common Stock (10906.00)	Indirect
2023-12-28	Stock Option (Right to Buy)	$10.13	G	35000.00	Disposed	2032-02-09	Common Stock (35000.00)	Direct
2023-12-28	Stock Option (Right to Buy)	$10.13	G	35000.00	Acquired	2032-02-09	Common Stock (35000.00)	Indirect

Footnotes

F1: This transaction was inadvertently left off of the original Form 4 filing on January 2, 2024.

F2: On December 28, 2023, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust.

F3: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023.

F5: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F6: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023.

F7: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024.

F8: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023.

F9: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.